FDA approves Corcept's Lifyorli for ovarian cancer months early The FDA approved Corcept Therapeutics' Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to three prior lines of differe...

Corcept Therapeutics catches a break with the approval of Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to three prior lines of treatments.
endpoints.news/fda-approves...

AI-Predicting Compound Affinity. We Aren't There Yet.

The latest AI/ML tools for co-folding proteins around small molecule ligands can produce impressive results.

Until you start looking at them closely.

Biotech Britain Vs. The World Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.

Biotech Britain Vs. The World:

insights.citeline.com/in-vivo/lead...

Evotec reveals sweeping 800-person layoffs, more site closures as restructuring rolls on Evotec has escalated its already substantial reorganization, plotting an additional round of layoffs and site closures that will

Evotec reveals sweeping 800-person layoffs, more site closures as restructuring rolls on

www.fiercebiotech.com/biotech/evot...

As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of 2024. | Eli Lilly continued staggering sales growth in the fourth quarter,...

www.fiercepharma.com/pharma/while...

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limi…

Fantastic review of Amylin and related peptides.

www.sciencedirect.com/science/arti...

Interpreting Confidence Intervals Interactive visualization of confidence intervals

#stats Here's a nifty interactive demo of confidence intervals by
Kristoffer Magnusson

rpsychologist.com/d3/ci/

An mRNA Refusal to File

What’s happening with Moderna’s mRNA flu vaccine at the FDA is awful, but unfortunately typical:

Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo Eli Lilly reports strong Q4 2025 with $19.29B revenue, led by tirzepatide sales. Company expects $80-83B revenue in 2026, contrasting with Novo Nordisk's projected decline.

Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo

Mapping the Genetics of Brown Fat - insitro How insitro unlocked population-scale human genetics in a tissue that has resisted measurement for decades – and what it reveals about peripheral approaches to metabolic disease The Furnace We Couldn’...

Mapping the Genetics of Brown Fat www.insitro.com/news/mapping...

From London to Lausanne: how Isomorphic Labs is rewriting drug discovery Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to "solve all diseases" with AI.

www.swissinfo.ch/eng/ai-and-m...

Biopharma Sentiment Index | Q1 2026 After four years of misery, the mood in biopharma strengthened meaningfully going into 2026, with across-the-board gains and early signs of a recovery that might finally stick.

Biopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.

endpoints.news/biopharma-se...

U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office A Science analysis reveals how many were fired, retired, or quit across 14 agencies

U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office | Science | AAAS www.science.org/content/arti...

The Lowdown on Low-Dose Aspirin for Primary Prevention Pivotal Randomized Trials and Guidelines

Eric Topol's post on 'The Lowdown on Low-Dose Aspirin for Primary Prevention'

erictopol.substack.com/p/the-lowdow...

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view

www.biopharmadive.com/news/jpm26-b...

JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.

JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview

www.biospace.com/business/dea...

Weight regain after cessation of medication for weight management: systematic review and meta-analysis Objectives To quantify and compare the rate of weight regain after cessation of weight management medications (WMMs) in adults with overweight or obesity. Design Systematic review and meta-analysis. ...

Weight regain after cessation of medication for weight management: systematic review and meta-analysis www.bmj.com/content/392/...

Watch: At #JPM26, former drug regulator Richard Pazdur rings the alarm about politics at FDA
Full session: www.statnews.com/2026/01/13/j...

Biotech on Fire: The Week Leading Into JPM 2026 Hello everyone! The early January vibe is traditionally shaped by JP Morgan Healthcare, but this year’s first week is unusually active, suggesting that maybe, afterall, 2026 could be a genuinely good ...

2026 pre JPM deal landscape is already heating up: www.linkedin.com/pulse/biotec...

Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses Milestone deal secures UK’s medicines access for patients, with a wide range of groundbreaking new treatments to reach NHS front-line quicker.

Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses

www.gov.uk/government/n...?

AI-Native Biotech Is an Opportunity for UK Leadership and Growth AI-Native Biotech Is an Opportunity for UK Leadership and Growth

AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC institute.global/insights/pub...

AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC

Nxera lays off 15% of staff, pivots pipeline focus in profitability push Nxera Pharma plans to lay off | Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.

Nxera lays off 15% of staff, pivots pipeline focus in profitability push www.fiercebiotech.com/biotech/nxer...

Nice perspective on the necessity of creating an ecosystem of innovation in the life sciences...

Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...

'The Evidence' on the BBC World Service where we discussed weight loss medications, which we recorded at the Wellcome Collection a couple of weeks ago #obesityisnotachoice www.bbc.com/audio/play/p...

Why is AI struggling to discover new drugs? via @ft

Autoimmune Disease, Transformed?

Dozens of clinical trials are underway trying to change the landscape of autoimmune disease therapy:

Is there a renaissance in GPCR drug development? Sitting at the top of many human signalling cascades, G-protein coupled receptors (GPCRs) play crucial roles in mood, sleep, appetite and every heartbeat. Historically challenging to develop, selectiv...

Is there a renaissance in GPCR drug development? www.nature.com/articles/d42...

Another GLP-1 Year

Questions about the GLP-1 agonist class that we might start resolving this year:

Probability isn’t a property of the world but a tool to navigate uncertainty conceived from subjective judgments and assumptions. #AcademicSky #NurseSky #PhilSky